biotech

How Aclaris Is On Track to Treat Baldness

Baldness and hair thinning is something that many men and women fear as they age, and understandably so. But Aclaris Therapeutics, Inc. (NASDAQ: ACRS) may have found an answer to ...
Read Full Story »

How Much Is Pfizer Overpaying For Array Bio?

Array BioPharma Inc. (NASDAQ: ARRY) shares shot up on Monday after the firm announced that it would be acquired by Pfizer Inc. (NYSE: PFE) in an all cash transaction. The ...
Read Full Story »

Investors Need Some Breathing Room From Savara’s Lung Treatment

Savara Inc. (NASDAQ: SVRA) shares were absolutely crushed on Thursday after the company released its late-stage results for its treatment of autoimmune pulmonary alveolar proteinosis (aPAP). Unfortunately, the study did ...
Read Full Story »

Multimillion-Dollar Medical Claims Continue to Skyrocket

Whether you were in favor of or against the Affordable Care Act, aka Obamacare, it is likely of little surprise that the cost of health care has continued to rise. ...
Read Full Story »

Big Biotechs Have Short Sellers on the Run

The short interest data are out for the most recent settlement date, May 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

New Sickle Cell Disease Treatment Could Be a Blockbuster With $1 Billion in Sales

Sickle cell disease impacts about 100,000 Americans, according to RethinkSCD.com. The incidence is about one in every 365 African American births and about one in every 16,300 Hispanic American births. ...
Read Full Story »

Meet the Newest Treatment for Autism Using Cannabidiol

With ever more states legalizing cannabis in the United States, it’s only a matter of time before it is legal across the country. After all, this drug does offer opportunities—outside ...
Read Full Story »

Is CymaBay Therapeutics’ Liver Disease Trial Sunk?

CymaBay Therapeutics Inc. (NASDAQ: CBAY) shares were nearly halved in Tuesday's premarket trading after the company provided an update from its midstage study of seladelpar for the treatment of nonalcoholic ...
Read Full Story »

Why NovaBay Pharma Shares Absolutely Exploded

NovaBay Pharmaceuticals Inc. (NYSE: NBY) shares absolutely exploded on Monday after the company announced that its eye care treatment would be readily available on Amazon. Specifically, its Avenova Direct is ...
Read Full Story »

5 ASCO Winners That Could Still More Than Double

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) has just concluded, and there were some significant moves we saw as a result. Wedbush took a closer ...
Read Full Story »

Is InflaRx Sunk by a Midstage Skin Condition Study?

InflaRx N.V. (NASDAQ: IFRX) shares were destroyed on Wednesday after the firm announced results from its midstage trial in patients suffering from moderate to severe hidradenitis suppurativa (HS). Prior to ...
Read Full Story »

Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO

It has been a tough year for many members of the so-called big pharma and big biotech. Also, in recent years, the lines separating the largest biotechs from the largest ...
Read Full Story »

Why Genocea’s Neoantigen Treatment Is Such a Big Hit at ASCO

Genocea Biosciences Inc. (NASDAQ: GNCA) is one of the big winners from the annual meeting of the American Society of Clinical Oncology (ASCO). The firm announced best-in-class clinical results from ...
Read Full Story »

Meet One of ASCO’s First Losers

Turning Point Therapeutics Inc. (NASDAQ: TPTX) shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small cell lung cancer patients. The data came ...
Read Full Story »

Why Cara Therapeutics Could Rise Another 50%

Cara Therapeutics Inc. (NASDAQ: CARA) recently announced data from its late-stage trial in patients with chronic kidney disease (CKD). While there was a very positive reaction among investors, one analyst ...
Read Full Story »